↓ Skip to main content

Cost-Effectiveness of Tucatinib in Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer From the US and Chinese Perspectives

Overview of attention for article published in Frontiers in oncology, August 2020
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (83rd percentile)
  • High Attention Score compared to outputs of the same age and source (95th percentile)

Mentioned by

news
2 news outlets
twitter
2 X users

Citations

dimensions_citation
34 Dimensions

Readers on

mendeley
50 Mendeley
Title
Cost-Effectiveness of Tucatinib in Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer From the US and Chinese Perspectives
Published in
Frontiers in oncology, August 2020
DOI 10.3389/fonc.2020.01336
Pubmed ID
Authors

Qiuji Wu, Weiting Liao, Mengxi Zhang, Jiaxing Huang, Pengfei Zhang, Qiu Li

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 50 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 50 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 6 12%
Other 5 10%
Student > Bachelor 3 6%
Student > Ph. D. Student 3 6%
Lecturer 2 4%
Other 6 12%
Unknown 25 50%
Readers by discipline Count As %
Medicine and Dentistry 8 16%
Pharmacology, Toxicology and Pharmaceutical Science 4 8%
Biochemistry, Genetics and Molecular Biology 2 4%
Social Sciences 2 4%
Nursing and Health Professions 1 2%
Other 7 14%
Unknown 26 52%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 14. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 November 2021.
All research outputs
#2,640,293
of 25,838,141 outputs
Outputs from Frontiers in oncology
#637
of 22,812 outputs
Outputs of similar age
#68,967
of 428,502 outputs
Outputs of similar age from Frontiers in oncology
#27
of 564 outputs
Altmetric has tracked 25,838,141 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 22,812 research outputs from this source. They receive a mean Attention Score of 3.1. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 428,502 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 83% of its contemporaries.
We're also able to compare this research output to 564 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 95% of its contemporaries.